Biocartis and Mayo Clinic collaborate
March 2026—Biocartis has entered into a research collaboration with Mayo Clinic to develop a rapid sample-to-answer test aiming to decrease the time to treatment for breast cancer patients.
Webinars and Sponsored Roundtables — Register Now
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace
Labcorp expands MRD testing
March 2026—Labcorp has expanded its molecular residual disease portfolio to include Labcorp Plasma Detect ID, a whole exome sequence–guided, personalized panel for patients with stages I–III breast cancer or stages I–IIIA non-small cell lung cancer, and Plasma Detect Genome, a whole genome MRD test for stage III colon cancer.
IDT unveils NGS portfolio
March 2026—Integrated DNA Technologies is releasing a suite of next-generation sequencing products that aim to tackle bottlenecks in library preparation, targeted enrichment, and whole genome analysis.
ARUP creates innovation central laboratory
March 2026—ARUP Laboratories has launched an innovation central laboratory to facilitate collaboration with pharmaceutical, biotechnology, and other industry partners.
Revvity launches somatic cancer reference standards
February 2026—Revvity launched highly characterized somatic cancer reference standards developed in collaboration with the Medical Device Innovation Consortium and National Institute of Standards and Technology as part of the Somatic Reference Samples Initiative.
CellaVision bone marrow aspirate application gets CE mark
February 2026—CellaVision’s bone marrow aspirate application has received the CE mark as a class C product under the European Union in vitro diagnostic regulation.
Fujifilm and Voicebrook partner
February 2026—Fujifilm Healthcare Americas Corp. and Voicebrook are partnering to integrate Voicebrook’s VoiceOver Pro with Fujifilm’s Synapse Pathology, a picture archiving and communication system designed to streamline case management.
BD launches new FacsDiscover A8 configurations
February 2026—BD released new configurations of its FacsDiscover A8 cell analyzers.
Octave, Quest expand access to Octave MSDA test
February 2026—Octave Bioscience is collaborating with Quest Diagnostics to make the Octave Multiple Sclerosis Disease Activity test accessible through Quest’s nationwide specimen-collection network.
Natera acquires Foresight Dx
February 2026—Natera has completed a transaction to acquire cancer diagnostics company Foresight Diagnostics.